Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech failure, 2002 -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (119)	10/23/2002 7:50:13 PM
From: keokalani'nui	Respond to of 130

Chiron Announces Discontinuation of SILCAAT and HBV-MF59 Trials And PA-1806 Program EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Chiron Corporation (Nasdaq: CHIR - News) announced today decisions on three clinical development programs. Chiron is stopping SILCAAT, a Phase III study for recombinant human interleukin-2 (IL-2, aldesleukin) in patients with HIV. Chiron had expected to complete the SILCAAT trial, including final patient follow-up, in 2007. The company is reviewing data for a possible regulatory submission that may allow approval of IL-2 only in a subset of patients who do not achieve immunological response while on highly active antiretroviral therapies (HAART). ADVERTISEMENT In addition, the company is terminating development of PA-1806, a compound for gram negative infections in cystic fibrosis patients, and HBV-MF59, an immunotherapy for patients with chronic hepatitis B infection. "We believe our decisions will enable Chiron to more effectively invest our resources to meet unmet medical needs and to advance our core franchises in cancer and infectious disease," said Craig Wheeler, President, Chiron BioPharmaceuticals ,[snip].

To: Icebrg who wrote (119)	12/11/2002 7:50:12 AM
From: Icebrg	Read Replies (1) \| Respond to of 130

Titan Announces Results of CeaVac Clinical Study in Colorectal Cancer Wednesday December 11, 7:31 am ET SOUTH SAN FRANCISCO, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Titan Pharmaceuticals, Inc. (ASE: TTP) announced today results of a Phase III, randomized, placebo-controlled study of its monoclonal antibody CeaVac® in patients with metastatic colorectal cancer receiving chemotherapy with 5- flourouracil (5-FU) and leucovorin. Preliminary analysis from the study demonstrated a trend toward overall survival improvement of approximately 2 to 3 months in patients receiving at least 5 doses of CeaVac versus placebo (modified intent-to-treat population) but failed to demonstrate a statistically significant improvement in the primary endpoint of survival in the overall efficacy evaluable population or intent-to-treat population. CeaVac is a monoclonal antibody that stimulates an immune response to carcinoembryonic antigen (CEA), and is administered as a subcutaneous injection. Patients in the study received injections of study drug once every two weeks for 2 months and then once per month thereafter. The study randomized 631 patients with previously untreated metastatic colorectal cancer to receive either CeaVac or placebo in combination with standard chemotherapy of 5-FU and leucovorin. Previous studies of CeaVac in advanced cancer patients had indicated that on average at least 5 injections of CeaVac were required to produce an immune response to CEA in such patients. For this reason, the study analysis included a modified intent-to-treat population of patients who had received at least 5 injections of study drug, which demonstrated a trend toward survival improvement for CeaVac versus placebo treated patients (19.1 versus 17.1 months, respectively). This trend was also present for patients receiving at least 8 doses of study drug (21.3 versus 18.5 months, respectively), as well as higher numbers of doses. However, many patients in the study did not receive more than a few doses of study drug and the resulting overall primary endpoint survival of patients receiving CeaVac was not different from those receiving placebo in the efficacy evaluable population (16.0 versus 15.6 months). "Although we are disappointed in the demonstrated preliminary results of this study analysis, we are continuing to evaluate the data to further determine any potential relationship between dose regimen and outcome," stated Dr. Louis R. Bucalo, Chairman, President and CEO of Titan. "Because this study was placebo controlled, we are in a good position to determine with further analysis if more extended dosing may be related to improved survival." Treatment with CeaVac was generally very well tolerated, with the most common side effect being some local injection site irritation. "We emphasized up front and throughout this study the need to continue treatment with CeaVac," stated Dr. Frank Valone, Executive Vice President of Clinical Development and Regulatory Affairs at Titan. "The safety profile to date is excellent, and with overall survival of approximately 15 months in the control population, we would have preferred to see average time on study drug in the range of 12 months. Because patients on average were on study drug for much less than this time period, our ability to demonstrate a treatment benefit may have been impacted," stated Dr. Valone. "We will continue to further analyze the study results, and believe these data in aggregate suggest biologic activity and the potential to improve survival with minimal side effects. We can potentially learn more from this study about the appropriate patient population and length of dosing regimen to achieve this goal." CeaVac is also being studied in combination with TriAb®, another Titan monoclonal antibody, in resected Dukes' D colorectal cancer, a less advanced stage of the disease. This Phase II study is supported by the National Cancer Institute and is being conducted by the Cancer and Leukemia Group B (CALGB). The Radiation Therapy Oncology Group (RTOG) is also conducting a Phase II study of CeaVac in combination with TriAb in non-small cell lung cancer.